A liberal red blood cell (RBC) transfusion strategy is suggested for hospitalized patients with acute myocardial infarction (AMI) when the hemoglobin concentration is less than 10 g/dL.

Get insights on Silence Therapeutics’ siRNA technology, clinical trial updates for polycythemia vera and Lp(a), and growth strategy.

Background The use of testosterone in gender-affirming hormone therapy for trans men is associated with several adverse effects. However, research on the risk of venous thromboembolism in this ...

Transfusion decisions should incorporate the clinical context rather than just the hemoglobin concentration ... liberal transfusion strategies based on hemoglobin concentrations or hematocrit levels ...

Company Also Announces SANRECO Phase 2 Study Has Exceeded 50% Enrollment - On-track for Full Enrollment by Year-End 2025 “The latest data presented at EHA today continue to demonstrate divesiran’s ...

Objective: Red blood cell (RBC) concentration impacts cerebrovascular disease, yet it is unclear whether RBC concentrations relate to dementia risk, particularly in racially/ethnically diverse cohorts ...

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced ...

LONDON--(BUSINESS WIRE)--$SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing ...

Introduction: The no-reflow phenomenon is considered to be one of the important mechanisms of ischemia-reperfusion injury. Low hematocrit (Hct) after hemodilution can increase microcirculation flow by ...

Background and Purpose: Heart failure is associated with renal dysfunction suggesting a pathophysiological link between heart and kidney. Empagliflozin, a SGLT2 inhibitor, showed beneficial effects on ...